ZA200608393B - Substituted methyl aryl or heteroaryl amide compounds - Google Patents

Substituted methyl aryl or heteroaryl amide compounds Download PDF

Info

Publication number
ZA200608393B
ZA200608393B ZA200608393A ZA200608393A ZA200608393B ZA 200608393 B ZA200608393 B ZA 200608393B ZA 200608393 A ZA200608393 A ZA 200608393A ZA 200608393 A ZA200608393 A ZA 200608393A ZA 200608393 B ZA200608393 B ZA 200608393B
Authority
ZA
South Africa
Prior art keywords
groups
carbon atoms
group
chloro
compound
Prior art date
Application number
ZA200608393A
Other languages
English (en)
Inventor
Koike Hiroki
Matsumoto Yukari
Yamagishi Tatsuya
Kon-I Kana
Okumura Yoshiyuki
Nakao Kazunari
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200608393(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ZA200608393B publication Critical patent/ZA200608393B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200608393A 2004-05-04 2006-10-06 Substituted methyl aryl or heteroaryl amide compounds ZA200608393B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56808804P 2004-05-04 2004-05-04

Publications (1)

Publication Number Publication Date
ZA200608393B true ZA200608393B (en) 2008-05-28

Family

ID=34982397

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200608393A ZA200608393B (en) 2004-05-04 2006-10-06 Substituted methyl aryl or heteroaryl amide compounds

Country Status (29)

Country Link
US (2) US7534914B2 (fr)
EP (1) EP1756042B8 (fr)
JP (1) JP4054368B2 (fr)
KR (1) KR20070006891A (fr)
CN (1) CN1950333A (fr)
AP (1) AP2006003785A0 (fr)
AR (1) AR048642A1 (fr)
AU (1) AU2005238291A1 (fr)
BR (1) BRPI0510666A (fr)
CA (1) CA2565813C (fr)
CR (1) CR8730A (fr)
DO (1) DOP2005000071A (fr)
EA (1) EA200601847A1 (fr)
EC (1) ECSP066968A (fr)
ES (1) ES2461265T3 (fr)
GT (1) GT200500101A (fr)
IL (1) IL178676A0 (fr)
MA (1) MA28571B1 (fr)
MX (1) MXPA06011555A (fr)
NL (1) NL1028947C2 (fr)
NO (1) NO20065578L (fr)
PA (1) PA8631201A1 (fr)
PE (1) PE20060306A1 (fr)
SV (1) SV2005002102A (fr)
TN (1) TNSN06358A1 (fr)
TW (1) TW200536541A (fr)
UY (1) UY28877A1 (fr)
WO (1) WO2005105732A1 (fr)
ZA (1) ZA200608393B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7446220B2 (en) 2005-09-19 2008-11-04 Teva Pharmaceutical Industries Ltd. Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid
EP1969129B1 (fr) 2005-12-28 2009-03-11 Basf Se Procédé de préparation du sulfate de l'ester méthylique d'acide 4-(1-aminoéthyl) benzoique (r) et (s) à partir de l'ester méthylique d'acide 4-(1-aminoéthyl) benzoique racémique
DE102005062966A1 (de) * 2005-12-28 2007-07-05 Basf Ag Verfahren zur Herstellung von (R)- und (S)-4-(Ammoniumethyl)benzoesäuremethylester-sulfat
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
CA2660133C (fr) * 2006-08-11 2015-10-27 Merck Frosst Canada Ltd. Derives de thiophenecarboxamide en tant que ligands du recepteur ep4
JP5069752B2 (ja) 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体
WO2009005076A1 (fr) 2007-07-03 2009-01-08 Astellas Pharma Inc. Composé amide
GB0721611D0 (en) * 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
PT2565191E (pt) 2008-05-14 2014-12-04 Astellas Pharma Inc Derivados do ácido 4-(indol-7- ilcarbonilaminometil)ciclo-hexanocarboxílico como antagonistas de receptores ep4, úteis no tratamento de insuficiência renal crónica ou de nefropatia diabética
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010087425A1 (fr) 2009-01-30 2010-08-05 国立大学法人京都大学 Inhibiteur de la progression du cancer de la prostate et procédé d'inhibition de la progression
CN105596320B (zh) 2009-04-22 2019-03-22 株式会社ＡｓｋＡｔ 癌症治疗用选择性ep4受体拮抗物质
CN107693518A (zh) * 2010-02-22 2018-02-16 株式会社ＡｓｋＡｔ Ep‑4受体拮抗剂在治疗il‑23介导疾病中的用途
CN103097358B (zh) * 2010-09-21 2015-04-08 卫材R&D管理有限公司 药物组合物
EP2649061B1 (fr) 2010-12-10 2015-05-13 Rottapharm Biotech S.r.l. Dérivés de pyridinamide en tant qu'antagonistes de récepteur ep4
ES2559513T3 (es) 2011-07-04 2016-02-12 Rottapharm Biotech S.R.L. Derivados de amina cíclica como antagonistas del receptor EP4
WO2013032977A1 (fr) 2011-08-29 2013-03-07 Ticona Llc Composition de polymère à cristaux liquides résistante à la chaleur ayant une faible température de fusion
US8669341B2 (en) 2011-08-29 2014-03-11 Ticona Llc Solid-state polymerization of a liquid crystalline polymer
CN103764793B (zh) 2011-08-29 2016-09-14 提克纳有限责任公司 高流动液晶聚合物组合物
TW201319023A (zh) 2011-08-29 2013-05-16 Ticona Llc 具改良低剪切黏度之熱向性液晶聚合物
US9057016B2 (en) 2011-08-29 2015-06-16 Ticona Llc Melt polymerization of low melt viscosity liquid crystalline polymers
US8778221B2 (en) 2011-08-29 2014-07-15 Ticona Llc Aromatic amide compound
WO2013032971A1 (fr) 2011-08-29 2013-03-07 Ticona Llc Substrat extrudé à l'état fondu destiné être utilisé dans des articles thermoformés
WO2013032967A1 (fr) 2011-08-29 2013-03-07 Ticona Llc Pièces coulées au moule formées à partir d'un polymère cristallin liquide
JP2014525498A (ja) 2011-08-29 2014-09-29 ティコナ・エルエルシー 高流動性液晶ポリマー組成物
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014130275A2 (fr) 2013-02-22 2014-08-28 Ticona Llc Composition de polymères haute performance présentant des propriétés d'écoulement améliorées
MX2015013328A (es) 2013-03-19 2016-02-26 Askat Inc Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago.
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
EP2991634A1 (fr) 2013-04-30 2016-03-09 Otitopic Inc. Formulations de poudre sèche et procédés d'utilisation
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
WO2014197659A1 (fr) 2013-06-07 2014-12-11 Ticona Llc Polymère à cristaux liquides thermotrope à haute résistance
US9593081B2 (en) 2013-06-12 2017-03-14 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
US9776964B2 (en) * 2013-12-17 2017-10-03 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
CN110621667A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 嘧啶衍生物
WO2018210994A1 (fr) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2
RS62441B1 (sr) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd N-supstituisani derivati indola
EP3625228B1 (fr) 2017-05-18 2021-07-07 Idorsia Pharmaceuticals Ltd Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
SK592017A3 (sk) * 2017-07-04 2019-01-08 Saneca Pharmaceuticals A. S. Spôsob prípravy morfínanových zlúčenín
CN111315363B (zh) 2017-09-22 2022-10-11 奥迪托皮克股份有限公司 含有硬脂酸镁的干粉组合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
PL4038052T3 (pl) * 2019-10-02 2024-08-26 Domain Therapeutics Antagoniści receptora ep4 prostaglandyny e2 (pge2)
WO2022037601A1 (fr) * 2020-08-18 2022-02-24 武汉人福创新药物研发中心有限公司 Dérivé de pyrazolamide servant d'antagoniste du récepteur ep4 et son utilisation dans la préparation de médicaments pour le traitement du cancer et de l'inflammation
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
BR9810733A (pt) 1997-04-04 2000-09-12 Pfizer Prod Inc Derivados de nicotinamida
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
JP2003500385A (ja) 1999-05-24 2003-01-07 コア・セラピューティクス，インコーポレイテッド Ｘａ因子阻害剤
US6924391B2 (en) * 2000-05-11 2005-08-02 Bristol-Myers Squibb Company Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors
ATE293109T1 (de) 2001-01-31 2005-04-15 Pfizer Prod Inc Nikotinsäureamid-derivate und ihre mimetika als inhibitoren von pde4-isozyms
RU2315746C2 (ru) 2001-08-09 2008-01-27 Оно Фармасьютикал Ко., Лтд. Производные карбоновых кислот и фармацевтическое средство, содержащее их в качестве активного ингредиента
WO2003030937A1 (fr) 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedes contre des maladies liees au stress comprenant des antagonistes de recepteurs mithochondriaux de la benzodiazepine

Also Published As

Publication number Publication date
BRPI0510666A (pt) 2007-12-04
ES2461265T3 (es) 2014-05-19
EA200601847A1 (ru) 2007-04-27
WO2005105732A8 (fr) 2007-04-19
SV2005002102A (es) 2005-12-13
US7534914B2 (en) 2009-05-19
UY28877A1 (es) 2005-12-30
CR8730A (es) 2006-11-30
CA2565813C (fr) 2010-10-26
MXPA06011555A (es) 2006-12-15
TNSN06358A1 (fr) 2008-02-22
AU2005238291A1 (en) 2005-11-10
US20050267170A1 (en) 2005-12-01
IL178676A0 (en) 2007-02-11
EP1756042B1 (fr) 2014-02-12
JP4054368B2 (ja) 2008-02-27
DOP2005000071A (es) 2005-11-30
NL1028947A1 (nl) 2005-11-07
TW200536541A (en) 2005-11-16
CN1950333A (zh) 2007-04-18
GT200500101A (es) 2005-12-12
KR20070006891A (ko) 2007-01-11
MA28571B1 (fr) 2007-05-02
WO2005105732A1 (fr) 2005-11-10
PA8631201A1 (es) 2005-11-25
NL1028947C2 (nl) 2006-04-10
JP2007536366A (ja) 2007-12-13
US20090163558A1 (en) 2009-06-25
EP1756042B8 (fr) 2014-06-04
US8084476B2 (en) 2011-12-27
EP1756042A1 (fr) 2007-02-28
AR048642A1 (es) 2006-05-10
ECSP066968A (es) 2006-12-29
CA2565813A1 (fr) 2005-11-10
AP2006003785A0 (en) 2006-10-31
PE20060306A1 (es) 2006-04-14
NO20065578L (no) 2007-01-12

Similar Documents

Publication Publication Date Title
EP1756042B1 (fr) Composes methylaryl- ou heteroarylamides substitues
CA2565660C (fr) Composes aryl- ou heteroarylamides ortho-substitues
EP1663979B1 (fr) Composes de phenyle ou de pyridyle amide utiles comme antagonistes de la prostaglandine e2
WO2006016218A1 (fr) Dérivés arylcarbonyliques ou hétéroarylcarbonyliques utiles comme antagonistes du récepteur vanilloïde de type 1 (vr1)
US20040204409A1 (en) Bicyclic compounds as NR2B receptor antagonists
WO2005095329A1 (fr) Composes a base de benzamides substitues en tant qu'antagonistes de recepteurs vr1